📊 CPMD Key Takeaways
Investment Thesis
CPMD exhibits severe financial distress with negative stockholders' equity of -$22.5M, indicating the company is technically insolvent and liabilities exceed all assets. The company is burning cash at an alarming rate with -$1.9M operating cash flow against only $1.2K in cash reserves, creating an immediate liquidity crisis. Negative gross margins of -127.8% suggest fundamental business model failure with the company losing money on every dollar of revenue.
CPMD Strengths
- Minimal capital expenditure requirements suggest asset-light operations
- Some revenue generation of $1.2M indicates ongoing business activity
- No recent insider sales in last 90 days
CPMD Risks
- Negative stockholders' equity of -$22.5M indicates technical insolvency
- Critical liquidity crisis with $1.2K cash against $34.1M liabilities and $7.0M long-term debt
- Negative gross margin of -127.8% indicates fundamental business model failure
- Operating cash burn of -$1.9M per period with minimal cash runway
- All profitability metrics deeply negative with net margin of -292.7%
- Current ratio of 0.05x indicates severe inability to meet short-term obligations
Key Metrics to Watch
- Cash position and runway to insolvency
- Gross margin trajectory toward positive territory
- Operating cash flow stabilization
CPMD Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CPMD Profitability Ratios
CPMD vs Healthcare Sector
How CANNAPHARMARX, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CPMD Balance Sheet & Liquidity
CPMD 5-Year Financial Trend
5-Year Trend Summary: CANNAPHARMARX, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.01 reflects profitable operations.
CPMD Growth Metrics (YoY)
CPMD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $312.2K | $188.4K | $0.00 |
| Q2 2025 | N/A | -$1.4M | $0.00 |
| Q1 2025 | $25.8K | -$690.6K | $0.00 |
| Q3 2024 | N/A | $188.4K | $0.00 |
| Q1 2024 | N/A | -$1.4M | $0.00 |
| Q3 2023 | N/A | -$564.4K | $0.00 |
| Q2 2023 | N/A | -$1.4M | $-0.01 |
| Q1 2023 | N/A | -$1.4M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CPMD Capital Allocation
CPMD SEC Filings
Access official SEC EDGAR filings for CANNAPHARMARX, INC. (CIK: 0001081938)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPMD
What is the AI rating for CPMD?
CANNAPHARMARX, INC. (CPMD) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPMD's key strengths?
Minimal capital expenditure requirements suggest asset-light operations. Some revenue generation of $1.2M indicates ongoing business activity.
What are the risks of investing in CPMD?
Negative stockholders' equity of -$22.5M indicates technical insolvency. Critical liquidity crisis with $1.2K cash against $34.1M liabilities and $7.0M long-term debt.
What is CPMD's revenue and growth?
CANNAPHARMARX, INC. reported revenue of $1.2M.
Does CPMD pay dividends?
CANNAPHARMARX, INC. does not currently pay dividends.
Where can I find CPMD SEC filings?
Official SEC filings for CANNAPHARMARX, INC. (CIK: 0001081938) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPMD's EPS?
CANNAPHARMARX, INC. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.